BidaskClub Lowers Ultragenyx Pharmaceutical (RARE) to Sell

Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an “in-line” rating to an “outperform” rating in a research note on Monday, January 22nd. Credit Suisse Group assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 17th. They set an “outperform” rating and a $67.00 target price on the stock. Raymond James Financial restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 15th. Finally, Canaccord Genuity set a $80.00 target price on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $72.06.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at $44.47 on Friday. Ultragenyx Pharmaceutical has a one year low of $41.67 and a one year high of $91.35.

A number of institutional investors have recently made changes to their positions in the business. B. Riley Financial Inc. purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $213,000. Opaleye Management Inc. purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $4,174,000. Virtus Fund Advisers LLC increased its stake in Ultragenyx Pharmaceutical by 149.8% in the fourth quarter. Virtus Fund Advisers LLC now owns 12,509 shares of the biopharmaceutical company’s stock valued at $580,000 after purchasing an additional 7,502 shares during the last quarter. Virtu Financial LLC purchased a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $342,000. Finally, UBS Asset Management Americas Inc. increased its stake in Ultragenyx Pharmaceutical by 6.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 26,662 shares of the biopharmaceutical company’s stock valued at $1,237,000 after purchasing an additional 1,636 shares during the last quarter. Institutional investors own 84.75% of the company’s stock.

WARNING: “BidaskClub Lowers Ultragenyx Pharmaceutical (RARE) to Sell” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/bidaskclub-lowers-ultragenyx-pharmaceutical-rare-to-sell.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply